Human Genome’s Lupus Drug Surprises Analysts

Shares in Human Genome Sciences increased by 277 percent on Monday after the company announced that their lupus drug Benlysta succeeded in a Phase III clinical trial. The announcement surprised many who were skeptical of the drug’s ability to live up to its claims. In the study, 57.6 percent of...

Special Report: Fighting the U.S. AIDS Epidemic

It’s a strange irony: Countries receiving U.S. funding for AIDS relief are required to have a strategic plan to fight the disease, but the U.S. doesn’t have a plan of its own. The U.S. Centers for Disease Control and Prevention (CDC) estimates that 1.2 million people in America have HIV, the virus that...

Medtronic Files for Pre-Market Approval for Epilepsy Device

Medtronic has filed for pre-market approval with the U.S. Food and Drug Administration for an implantable device to help patients with severe, treatment-resistant epilepsy. Medtronic Deep-Brain Stimulation(DBS) Therapy is designed to treat patients with uncontrollable seizures who do not respond to...

CSI Enrolls First Patient in Study of Vascular Device

Cardiovascular Systems, a medical device company that specializes in the treatment of vascular diseases, has enrolled the first patient in its COMPLIANCE 360°  clinical trial. The prospective study will generate additional data on the effectiveness of CSI’s Diamondback 360°  Peripheral Arterial...

New Developments in Detecting and Treating Alzheimer’s

Every 70 seconds, someone develops Alzheimer’s disease. This startling figure from the Alzheimer’s Association underlines the desperate need for new tools to diagnose and treat this debilitating illness. Recent scientific developments are offering new hope for the estimated 5.3 million...

FDA Approves First Maintenance Therapy Drug for Lung Cancer

 Lung cancer treatment typically plays out in stages: Doctors administer a first-line treatment such as chemotherapy or Avastin, wait to see if the tumor progresses, and then administer a second-line treatment such as Alimta or Tarceva. Now, two pharmaceutical companies are eager to advance a different...

CBCE Launches Continuing Education App for iPhone

Healthcare providers on the go can now download their favorite tunes while learning about the latest advances in cancer care. The Center for Biomedical Continuing Education (CBCE), a full-service provider of continuing medical education (CME), has launched an oncology-focused CME application for the iPhone...

Foresight’s Conjunctivitis Solution Beats Competitors In Study

Adenoviral conjunctivitis, commonly known as “pink eye,” is one of the most contagious and widespread eye diseases. It can be several uncomfortable days before the redness, crusting, and irritation associated with pink eye begin to abate. There is a significant clinical need for a treatment...